Clinical trial · Interventional
Combination Chemotherapy in Treating Young Male Patients With Hodgkin's Lymphoma
Pilot Study for Therapy Optimising for Hodgkin's Lymphoma in Childhood and Adolescence; Optimising Therapy for Boys With Hodgkin's Lymphoma in Intermediate and Advanced Stages. Safety and Efficacy Study for Drug Combination VECOPA
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving combination chemotherapy may kill more cancer cells. PURPOSE: This phase II trial is studying the side effects and how well combination chemotherapy works in treating young male patients with Hodgkin's lymphoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lymphoma | Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (7)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| cyclophosphamide | Drug | Cyclophosphamide | ALIAS |
| doxorubicin hydrochloride | Drug | Doxorubicin | ALIAS |
| etoposide | Drug | Etoposide | ALIAS |
| prednisone | Drug | Prednisone | ALIAS |
| radiation therapy | Radiation | — | UNRESOLVED |
| vinblastine sulfate | Drug | Vinblastine | ALIAS |
| vincristine sulfate | Drug | Vincristine | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- VECOPA
- description
- dose and time intensified consoloditation chemotherapy cycle
- interventionNames
- Drug: cyclophosphamide
- Drug: doxorubicin hydrochloride
- Drug: etoposide
- Drug: prednisone
- Drug: vinblastine sulfate
- Drug: vincristine sulfate
- Radiation: radiation therapy
Primary outcomes (1)
- measure
- Toxicity at days 21 and 42 (+/- 2 days) of treatment
- timeFrame
- days 21 and 42 (+/- 2 days) of treatment after start of VECOPA cycle
- description
- number of VECOPA cycles that allow continuation of chemotherapy on a sufficient hematopoietic recovery
Secondary outcomes (2)
Eligibility
Eligibility (as posted)
- Sex
- Male
- Maximum age
- 18 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Diagnosis of classic Hodgkin's lymphoma (HL) * Intermediate or advanced disease (stage I\[E\]-IV) * No lymphocyte-predominant HL * Previously untreated disease PATIENT CHARACTERISTICS: * Male * No known hypersensitivity or contraindication to study drugs * No other concurrent malignancies * No severe concurrent diseases (e.g., immune deficiency syndrome) * No known HIV positivity PRIOR CONCURRENT THERAPY: * See Disease Characteristics * No prior chemotherapy or radiotherapy * More than 30 days since prior and no other concurrent investigational drugs * More than 30 days since prior and no concurrent participation in another clinical trial
References
Publications (0)
Data not yet available